Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies

References

• Busch W. Aus der Sitzung der medicinischen Section vom 13 November 1867. Berl Klin Wochenschr. 1868;5: 137. (in German).
   Google Scholar
• Fehleisen F. Ueber die Züchtung der Erysipelkokken auf künstlichem Nährboden und ihre übertragbarkeit auf den Menschen. Dtsch Med Wochenschr. 1882;8: 553–554. (in German).
   Google Scholar
• McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006;26:154.
   Google Scholar
• Allison JP, McIntyre BW, Bloch D. Tumor-specific antigen of murine T lymphoma cells defined with monoclonal antibody. J Immunol. 1982;129:2293–2300.
   Google Scholar
• Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643–1647.
   Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–1736.
   Google Scholar
• Cancer Research Institute [Internet]. New York (NY): CRI. [cited 2018 Oct 1]. Available from: www.cancerresearch.org/news/2011/fda-approves-new-immunotherapy-for-melanoma
   Google Scholar
• NobelPrize.org [Internet]. Solna: The Karolinska Institute. [cited 2018 Oct 1]. Available from: www.nobelprize.org/prizes/medicine/2018/press-release
   Google Scholar
• Brahmer JR, Lacchetti C, Thompson JA. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline summary. J Oncol Pract. 2018 Mar 8;14(4):247–249.
   Google Scholar
• Haanen JB, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv119–iv142.
   Google Scholar
• Nagai H, Muto M. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. Int J Clin Oncol. 2018. DOI:10.1007/s10147-018-1259-6
   Google Scholar
• González-Rodríguez E, Rodríguez-Abreu D. Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist. 2016;21(7):804–816.
   Google Scholar
• Wang Y, Abu-Sbeih H, Mao E, et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer. 2018 Dec;6(1):37.
   Google Scholar
• Moore C, Chen I. Immunotherapy in cancer treatment: a review of checkpoint inhibitors. US Pharm. 2018;43(2):27–31.
   Google Scholar
• Sharpe AH. Introduction to checkpoint inhibitors and cancer immunotherapy. Immunol Rev. 2017;276:5–8.
   Google Scholar
• Chascsa DM, Rakela J. Knowns and unknowns: the safety and efficacy of cancer immunotherapy in chronic liver disease. Curr Hepatol Rep. 2018;17:153.
   Google Scholar
• Wang W, Lie P, Guo M, et al. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta- analysis of published data. Int J Cancer. 2017;141:1018–1028.
   Google Scholar
• Rivoltini L, Carrabba M, Huber V, et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev. 2002;188:97–113.
   Google Scholar
• Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7(2):95–106.
   Google Scholar
• Nagorsen D, Scheibenbogen C, Marincola FM, et al. Natural T cell immunity against cancer. Clin Cancer Res. 2003 Oct 1;9(12):4296–4303.
   Google Scholar
• Tarhini A. Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo). 2013;2013:857519.
   Google Scholar
• Engelhardt JJ, Sullivan TJ, Allison JP. CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J Immunol. 2006;177(2):1052–1061.
   Google Scholar
• Wang W, Lau R, Yu D, et al. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25Hi regulatory T cells. Int Immunol. 2009 Aug 3;21(9):1065–1077.
   Google Scholar
• Lacroix M. Targeted therapies in cancer. Hauppauge (NY):Nova Science Pub Inc; 2014.
   Google Scholar
• Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother. 2009;58(5):823–830.
   Google Scholar
• Robert C, Ghiringhelli F. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist. 2009;14(8):848–861.
   Google Scholar
• Kaehler KC, Piel S, Livingstone E, et al. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol. 2010;37(5):485–498.
   Google Scholar
• Oble DA, Mino-Kenudson M, Goldsmith J, et al. Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am J Surg Pathol. 2008;32(8):1130–1137.
   Google Scholar
• Shah N, Puthiamadathil J, Serzan M, et al. Clinical Outcome of immune related hepatitis (IrHep) in patients with advanced melanoma (AM) treated with single agent or combination immune checkpoint inhibitors (ICI) [abstract]. Ann Oncol. 2018 Oct;29(8):viii433.
   Google Scholar
• Hodi FS, O’day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711–723.
   Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun 30;364(26):2517–2526.
   Google Scholar
• Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. https://clinicaltrials.gov/ct2/home [Internet]. Bethesda (MD): National Library of Medicine (US); 2018 10 1. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01285609?term=ipilimumab%2C+carboplatin&draw=2&rank=5.NCT01285609.
   Google Scholar
• Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2012 Aug 2;24(1):75–83.
   Google Scholar
• Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. https://clinicaltrials.gov/ct2/home [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2018 Oct 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT00861614.NCT00861614
   Google Scholar
• Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. https://clinicaltrials.gov/ct2/home [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2018 Oct 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT00636168.NCT00636168
   Google Scholar
• Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. https://clinicaltrials.gov/ct2/home [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2018 Oct 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT00257205.NCT00257205
   Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015 Jan 22;372(4):320–330.
   Google Scholar
• Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. Journal of Clinical Oncology 2017;(35:7):785-792.
   Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015 Jul 9;373(2):123–135.
   Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627–1639.
   Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. https://clinicaltrials.gov/ct2/home [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2018 Oct 1]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02108652:NCT02108652
   Google Scholar
• Jotte RM, Cappuzzo F, Vynnychenko I, et al. IMpower131: primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin+ nab-paclitaxel as 1L therapy in advanced squamous NSCLC. Journal of Clinical Oncology. 2018;36(18_suppl):LBA9000-LBA9000.
   Google Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015 May 21;372(21):2006–2017.
   Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015 Jul 2;373(1):23–34.
   Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013 Jul 11;369(2):122–133.
   Google Scholar
• Parlati L, Vallet-Pichard A, Batista R, et al., Mallet V for the CETRIM group. Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: a retrospective study. J Hepatol. 2018;69(6):1396–1397.
   Google Scholar
• Alessandrino F, Tirumani SH, Krajewski KM, et al. Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors. Clin Radiol. 2017 Jul 1;72(7):521–533.
   Google Scholar
• Suzman DL, Pelosof L, Rosenberg A, et al. Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int. 2018 Jun;38(6):976–987.
   Google Scholar
• Cancer Therapy Evaluation Program [Internet]. Bethesda (MD): NIH. [cited 2018 Oct 1]. Available from: https://ctep.cancer.gov/protocoldevelopment/_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
   Google Scholar
• Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group. J Immunother Cancer. 2017 Dec;5(1):95.
   Google Scholar
• Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. Dec 1;4(12):1721-1728.
   Google Scholar
• Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Nat Acad Sci. 2003 Jul 8;100(14):8372–8377.
   Google Scholar
• Weber JS, Dummer R, de Pril V, et al. MDX010‐20 Investigators. Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. https://clinicaltrials.gov/ct2/home [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2018 Oct 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT00094653:NCT00094653
   Google Scholar
• Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691–2697.
   Google Scholar
• Yervoy (Ipilimumab) [Package Insert]. Princeton (NJ): Bristol-Myers Squibb; 2017.
   Google Scholar
• Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. https://clinicaltrials.gov/ct2/home [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2018 Oct 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT00289640:NCT00289640
   Google Scholar
• Ribas A, Hodi FS, Callahan M, et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013 Apr 4;368(14):1365–1366.
   Google Scholar
• Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). https://clinicaltrials.gov/ct2/home [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2018 Oct 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01866319:NCT01866319
   Google Scholar
• Zarabi K, Wu S. Risk of liver toxicity with nivolumab immunotherapy in cancer patients. Oncology. 2018;94:259–273.
   Google Scholar
• Eigentler TK, Hassel JC, Berking C, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016 Apr 1;45:7–18.
   Google Scholar
• Janjigian YY, Bendell J, Calvo E, et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J clin oncol. 2018 May 18;36(28):2836-2844.
   Google Scholar
• Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. https://clinicaltrials.gov/ct2/home [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2018 Oct 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01704287:NCT01704287
   Google Scholar
• Wang PF, Chen Y, Song SY, et al. Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 2017 Oct 18;8:730.
   Google Scholar
• De Martin E, Michot JM, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018 Jun 1;68(6):1181–1190.
   Google Scholar
• Huffman BM, Kottschade LA, Kamath PS, et al. Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management. Am J Clin Oncol.
   Google Scholar
• Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018;31:965–973.
   Google Scholar
• Kleiner DE, Berman D. Pathologic changes in ipilimumab- related hepatitis in patients with metastatic melanoma. Dig Dis Sci. 2012;57:2233–2240.
   Google Scholar
• Johncilla M, Misdraji J, Pratt DS, et al. Ipilimumab-associated Hepatitis. Am J Surg Pathol. 2015 Aug 1;39(8):1075–1084.
   Google Scholar
• Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs. 2013 Aug 1;31(4):1071–1077.
   Google Scholar
• Everett J, Srivastava A, Misdraji J. Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis. Am J Surg Pathol. 2017;41:134–137.
   Google Scholar
• Lewis JH. Chapter 40. Granulomas of the liver. In: Schiff ER, Maddrey WC, Reddy KR, editors Schiff’s disease of the liver. 12th ed. Wiley-Blackwell New Jersey, USA. 2018. p. 1028–1052.
   Google Scholar
• Aguilar-Olivos N, Del Carmen Manzano-Robleda M, Gutiérrez-Grobe Y, et al. Granulomatous hepatitis caused by Q fever: a differential diagnosis of fever of unknown origin. Ann Hepatol. 2013 Jan 15;12(1):138–141.
   Google Scholar
• Pellegrin M, Delsol G, Auvergnat JC, et al. Granulomatous hepatitis in Q fever. Hum Pathol. 1980 Jan 1;11(1):51–57.
   Google Scholar
• Reddy HG, Schneider BJ, Tai AW. Immune Checkpoint Inhibitor-Associated Colits and Hepatitis. Clin Transl Gastroenterol. 2018;9:180.
   Google Scholar
• Doherty GJ, Duckworth AM, Davies SE, et al. Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. ESMO Open. 2017 Oct 1;2(4):e000268.
   Google Scholar
• Kawakami H, Tanizaki J, Tanaka K, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs. 2017 Aug 1;35(4):529–536.
   Google Scholar
• Björnsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51:2040–2048.
   Google Scholar
• Björnsson ES, Bergmann O, Jonasson JG, et al. Drug-induced autoimmune hepatitis: response to corticosteroids and lack of relapse after cessation of steroids. Clin Gastroenterol Hepatol. 2017 Oct 1;15(10):1635–1636.
   Google Scholar
• Martínez‐Casas OY, Díaz‐Ramírez GS, Marín‐Zuluaga JI, et al. Differential characteristics in drug‐induced autoimmune hepatitis. JGH Open.
   Google Scholar
• Wang H, Fu J, Liu G, et al. Drug induced autoimmune hepatitis (DIAIH): pathological and clinical study. Biomed Res. 2017;28:13.
   Google Scholar
• Oliveira LC, Porta G, Marin MLC, et al. Autoimmune hepatitis, HLA and extended haplotypes. Autoimmun Rev. 2011;10:189‐193.
   Google Scholar
• Abu-Sbeih H, Tang T, Ali FS, et al. The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients’ outcomes. J Immunother Precis Oncol. 2018. 1;1. Jan(1):7.
   Google Scholar
• Sznol M, Ferrucci PF, Hogg D, et al. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol. 2017 Dec 1;35(34):3815–3822.
   Google Scholar
• Sarmen S, Tara S. Acute liver failure from anti-PD-1 antibody nivolumab in a patient with metastatic lung squamous cell carcinoma. Austin Oncol. 2016;1(2):1006.
   Google Scholar
• Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2016 Sep 29;28(2):368–376.
   Google Scholar
• Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2:234–240.
   Google Scholar
• Abdel-Wahab N, Shah M, Lopez-Olivo MA, et al. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic re-view. Ann Intern Med. 2018;168(2):121–130.
   Google Scholar
• US Food & Drug Administration [Internet]. Silver Spring (MD): FDA. [cited 2018 Oct 1]. Available from: https://www.fda.gov/Drugs/default.htm
   Google Scholar
• Sanjeevaiah A, Kerr T, Beg MS. Approach and management of checkpoint inhibitor-related immune hepatitis. J Gastrointest Oncol. 2018 Feb;9(1):220.
   Google Scholar
• Chmiel KD, Suan D, Liddle C, et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J clin oncol. 2011 Jan 10;29(9):e237–e240.
   Google Scholar
• Gauci M, Baroudjian B, Zeboulon C, et al. Lebbe C for the PATIO group. Immune-related hepatitis with immunotherapy: are corticosteroids always needed? J Hepatol. 2018;69:548–550.
   Google Scholar
• Evaluation and Management of Suspected Immune-Mediated Colitis/Diarrhea [Internet]. Houston (TX): MD Anderson Cancer Center. [cited 2018 Oct 1]. Available from: https://www.mdanderson.org/content/dam/mdanderson/documents/for-physicians/algorithms/clinical-management/clin-management-immune-mediated-colitis-web-algorithm.pdf
   Google Scholar
• Santini FC, Rizvi H, Wilkins O, et al. Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD (L)-1 therapy.
   Google Scholar
• Pollack MH, Betof A, Dearden H, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2017 Oct 11;29(1):250–255.
   Google Scholar
• Ziemer M, Koukoulioti E, Beyer S, et al. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Hepatol. 2017 Mar 1;66(3):657–659.
   Google Scholar
• Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010 Oct 1;139(4):1198–1206.
   Google Scholar
• Baecher-Allan C, Brown JA, Freeman GJ, et al. CD4+CD25 high regulatory cells in human peripheral blood. J Immunol. 2001;167:1245–1253.
   Google Scholar
• Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8:523–532.
   Google Scholar
• Stoop JN, van der Molen RG, Baan CC, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology. 2005;41:771–778.
   Google Scholar
• Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12:492–499.
   Google Scholar
• Ravi S, Spencer K, Ruisi M, et al. Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series. J Immunother Cancer. 2014 Dec;2(1):33.
   Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. https://clinicaltrials.gov/[Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2018 Oct 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01658878?term=NCT01658878&rank=1.NCT01658878
   Google Scholar
• Reddy KR, Beavers KL, Hammond SP, et al. American gastroenterological association institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:215–219.
   Google Scholar
• Koksal AS, Toka B, Eminler AT, et al. HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma. Ann Oncol. 2017 Sep 4;28(12):3103–3104.
   Google Scholar
• Schrem H, Speck M, Vogel A, et al. Incidence and prognosis of de Novo Malignancies after liver transplantation: 2033. Transplantation. 2012 Nov 27;94(10S):226.
   Google Scholar
• Munker S, De Toni EN. Use of checkpoint inhibitors in liver transplant recipients. United European Gastroenterol J. 2018;6:970–973.
   Google Scholar
• Barnett R, Barta VS, Jhaveri KD. Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab. N Engl J Med. 2017;376:191–192.
   Google Scholar
• De Toni EN, Gerbes AL. Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient. Gastroenterology. 2017;152:1631–1633.
   Google Scholar
• Bhave P, Buckle A, Sandhu S, et al. Mortality due to immunotherapy related hepatitis. J Hepatol. 2018;69:976–978.
   Google Scholar
• Riveiro-Barciela M, Munoz-Couselo E, Fernandez-Sojo J, et al. Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: new settings call for new treatment strategies? J Hepatol. 2018 Nov 28. Epub ahead of print.
   Google Scholar
• Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J clin oncol. 2015 Oct 1;33(28):3193.
   Google Scholar